Related Experiment Video
Updated: Jun 16, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
[Histone deacetylase inhibitors as therapeutic agents for polyglutamine disorders]
Hong Jiang1, Dandan Jia, Beisha Tang
1Department of Neurology, Xiangya Hospital; Neurodegenerative Disorders Research Center, Central South University, Changsha, Hunan, 410008 P.R.China. jianghong73868@yahoo.com.cn
Abstract:
During the past few years, gene expression studies have shown that the perturbation of transcription frequently results in neuronal dysfunction in polyglutamine (PolyQ) diseases such as Huntington's disease (HD). Histone deacetylases (HDACs) act as repressors of transcription through interaction with co-repressor complexes, leading to chromatin remodelling. Aberrant interaction between PolyQ proteins and regulators of transcription could be one mechanism by which transcriptional dysregulation occurs. Here, the authors discuss the possible mechanism of transcriptional dysfunction in PolyQ disease, including the effect of histone acetyltransferases (HATs) and HDACs on pathogenesis, and the potential therapeutic pathways through which histone deacetylase inhibitors (HDACIs) might act to correct the aberrant transcription observed in HD and other PolyQ diseases.
Related Concept Videos
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Huntington Disease l: Introduction
Pharmacogenomics: Identification of New Drug Targets
Anthelminthic Agents
Alzheimer's Disease: Treatment

